Logo

Compugen Reports $281K Q1 Revenues

May 14, 2008
NEW YORK (GenomeWeb News) – Compugen today reported first-quarter revenues of $281,000 versus no revenues in the comparable period a year ago.
 
The Tel Aviv, Israel-based developer of predictive drug discovery platforms posted a net loss of $2.5 million, or $.09 per share, down 19.4 percent from a net loss of $3.1 million, or $.11 per share, for the first quarter of 2007.
 
Compugen’s R&D expenses decreased 10 percent to $1.8 million from $2 million, and its SG&A costs increased 9 percent to $1.2 million from $1.1 million.
 
The firm held cash, cash equivalents, deposits, and marketable securities of $14.8 million as of March 31.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.